Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589080 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2NOD1FOLH1GSTK1 | |
| SCHEMBL4588679 | 0.84 | PTGS1 (0.38) | PTGS1PTGS2NOD1 | |
| SCHEMBL4587653 | 0.84 | NOD1 (0.42) | PTGS1PTGS2NOD1FOLH1GSTK1 | |
| SCHEMBL4587282 | 0.84 | NOD1 (0.42) | PTGS1PTGS2NOD1FOLH1GSTK1 | |
| SCHEMBL4587729 | 0.83 | NOD1 (0.43) | PTGS1PTGS2NOD1FOLH1GSTK1 | |
| SCHEMBL4586370 | 0.83 | NOD1 (0.43) | PTGS1PTGS2NOD1FOLH1GSTK1 | |
| SCHEMBL4587050 | 0.81 | NOD1 (0.37) | PTGS1NOD1FOLH1GSTK1GLO1 | |
| SCHEMBL4588742 | 0.81 | NOD1 (0.39) | PTGS1PTGS2NOD1GSTK1 | |
| SCHEMBL4587325 | 0.81 | NOD1 (0.39) | PTGS1PTGS2NOD1GSTK1 | |
| SCHEMBL4588699 | 0.80 | NOD1 (0.39) | PTGS1PTGS2NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | PTGS1 83/4885PTGS2 177/4885NOD1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.